Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trialMeinolf Karthaus, Peter Reichardt, Albrecht Kretzschmar et al.|Annals of Oncology|2005Cited by 223
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)Kathrin Heinrich, Dominik Paul Modest, Lothar Mueller et al.|ESMO Open|2023Cited by 10
Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).Dominik Paul Modest, Tanja Trarbach, Meinolf Karthaus et al.|Journal of Clinical Oncology|2021Cited by 6
Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trialMeinolf Karthaus, Volker Heinemann, Jorge Riera‐Knorrenschild et al.|BMC Cancer|2024Cited by 3
P-149 Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysisAlberto F. Sobrero, Marc Peeters, Jean‐Yves Douillard et al.|Annals of Oncology|2016Cited by 2